{"altmetric_id":4687474,"selected_quotes":["For more information on the ALLSTAR Phase I\/II #clinicaltrial please visit this link --","#clinicaltrials enrolling patients to cure heart failure with #stemcells $capr #trialsloop"],"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Capricor Inc."],"first_seen_on":"2015-10-28T12:27:34+00:00","isbns":[],"issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1495476671,"links":["http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01458405","http:\/\/clinicaltrials.gov\/show\/NCT01458405","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01458405","https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01458405","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01458405?utm_content=buffer5faae&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01458405?term=cap-1002&phase=1&rank=3","https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01458405?term=allstar&rank=1&show_locs=Y#locn"],"nct_id":"NCT01458405","pubdate":"2011-10-20T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration (ALLSTAR)","type":"clinical_trial_study_record"},"altmetric_score":{"score":48.6,"score_history":{"1y":21,"6m":21,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":48.6},"context_for_score":{"all":{"total_number_of_other_articles":8250529,"mean":6.9707556030289,"rank":187568,"this_scored_higher_than_pct":97,"this_scored_higher_than":8062974,"rank_type":"exact","sample_size":8250529,"percentile":97},"similar_age_3m":{"total_number_of_other_articles":244054,"mean":9.8073732918669,"rank":9759,"this_scored_higher_than_pct":95,"this_scored_higher_than":234290,"rank_type":"exact","sample_size":244054,"percentile":95},"this_journal":{"total_number_of_other_articles":23837,"mean":10.370261872797,"rank":650,"this_scored_higher_than_pct":97,"this_scored_higher_than":23186,"rank_type":"exact","sample_size":23837,"percentile":97},"similar_age_this_journal_3m":{"total_number_of_other_articles":1103,"mean":14.609987295826,"rank":47,"this_scored_higher_than_pct":95,"this_scored_higher_than":1056,"rank_type":"exact","sample_size":1103,"percentile":95}}},"demographics":{"poster_types":{"member_of_the_public":4},"users":{"twitter":{"cohorts":{"Members of the public":4}}},"geo":{"twitter":{"US":3,"MX":1}}},"counts":{"total":{"posts_count":14},"news":{"unique_users_count":6,"unique_users":["u_t_san_diego","bioportfolio","the_scientist_magazine","noodls","seeking_alpha","medpage_today"],"posts_count":9},"twitter":{"unique_users_count":4,"unique_users":["Capricor_News","TrialsLoop","StemCellMarket","drjosorio"],"posts_count":4},"facebook":{"unique_users_count":1,"unique_users":["1516139925282376"],"posts_count":1}},"posts":{"news":[{"title":"Stem cells tested to repair damaged hearts","url":"http:\/\/www.utsandiego.com\/news\/2013\/Dec\/26\/heart-attack-stem-cells-capricor-allstar-cardiac\/","license":"public","citation_ids":[4687474],"posted_on":"2013-12-27T02:58:57+00:00","summary":"Heart attack patients are getting a new stem cell therapy to regenerate dead heart muscle.","author":{"name":"U-T San Diego","url":"http:\/\/utsandiego.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/299\/normal\/Screen_Shot_2016-02-02_at_14.43.04.png?1454424196"}},{"title":"Capricor Therapeutics: ALLSTAR Thoughts about Janssen's Option to License","url":"http:\/\/ct.moreover.com\/?a=27780053548&p=1pl&v=1&x=uJudC95urg05kNegX8B1wQ","license":"public","citation_ids":[4687474],"posted_on":"2016-08-30T02:45:00+00:00","summary":"Printed From BioPortfolio.com Capricor Therapeutics (CAPR) has key milestones arriving over the next several months.","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}},{"title":"Exosomes Vital for Heart Repair","url":"http:\/\/www.the-scientist.com\/?articles.view\/articleNo\/39900\/title\/Exosomes-Vital-for-Heart-Repair\/","license":"public","citation_ids":[2332240,2332240,1749014,1410069,4687474],"posted_on":"2014-05-06T17:02:00+00:00","summary":"Reparations after a heart attack in mice depend not on stem cells, but the exosomes they secrete.","author":{"name":"The Scientist Magazine","url":"http:\/\/www.the-scientist.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/096\/normal\/image.png?1369860108"}},{"title":"Phase II adult stem cell therapy heart attack study underway","url":"http:\/\/ct.moreover.com\/?a=25810444053&p=1pl&v=1&x=6X2USTTmwf7A1Y8N1vvRBA","license":"public","citation_ids":[4687474],"posted_on":"2016-03-14T22:27:40+00:00","summary":"The University of Kansas Medical Center (via noodls) \/ March 14, 2016 Repairing damaged heart muscle with adult cardiac stem cells is the goal of a new clinical trial currently recruiting participants in the Kansas City area.","author":{"name":"Noodls","url":"http:\/\/www.noodls.com\/index.asp","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/955\/normal\/Screen_Shot_2016-02-11_at_11.48.48.png?1455191394"}},{"title":"Is It Time To Invest In Stem Cell Biotechs?","url":"http:\/\/ct.moreover.com\/?a=26762268609&p=1pl&v=1&x=oVTh-ItiI0j7FDbPI-5anQ","license":"public","citation_ids":[1483641,8461015,5023674,4687912,4685247,8461016,1227556,2778354,4486171,1501479,8461017,4687917,8461018,4687474,4685288,6946725,8461019,4684997,4686296,4372520,1918044,4813493],"posted_on":"2016-06-03T11:17:55+00:00","summary":"Stem cell therapies are a key component of regenerative medicine, a medical field that holds many great promises.","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}},{"title":"Introduction and Update to Capricor Therapeutics (CAPR)","url":"http:\/\/ct.moreover.com\/?a=27051838069&p=1pl&v=1&x=eQEmW_SiGtOwUUOh2HpcMA","license":"public","citation_ids":[4683838,4685288,4687474],"posted_on":"2016-06-26T23:16:04+00:00","summary":"Printed From BioPortfolio.com Company Introduction Capricor Therapeutics (CAPR) is a small Beverly Hills biopharmaceutical developing treatments for the heart and other organs.","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}},{"title":"Capricor Reports Q4-2016","url":"http:\/\/ct.moreover.com\/?a=29911689426&p=1pl&v=1&x=QxeqZk_9buP2mYV8DBkoMg","license":"public","citation_ids":[4685288,4687474],"posted_on":"2017-03-15T22:16:00+00:00","summary":"Printed From BioPortfolio.com On Wednesday, March 15, 2017, Capricor Therapeutics (CAPR) announcedQ4 & FY-2016 results and held a conference call.","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}},{"title":"Interim data not good for Capricor's lead product candidate in mid-stage heart study, focus shifts to DMD; job cuts planned; shares off 33% premarket","url":"http:\/\/ct.moreover.com\/?a=30543256399&p=1pl&v=1&x=3ubXE8kECMh2FIK3VPy5BA","license":"public","citation_ids":[4687474],"posted_on":"2017-05-12T11:09:22+00:00","summary":"Thinly traded nano cap Capricor Therapeutics (NASDAQ: CAPR ) plummets 33% premarket on light volume in response to its announcement that its Phase 2 clinical trial, ALLSTAR, assessing lead product candidate CAP-1002 for the treatment of adults who\u2026","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}},{"title":"Dissecting the Press Release for a Failed Stem Cell Trial","url":"http:\/\/ct.moreover.com\/?a=30655642071&p=1pl&v=1&x=hOHDF4zNvFFm8Bc0BtU-2w","license":"public","citation_ids":[4687474],"posted_on":"2017-05-22T18:11:11+00:00","summary":"Stem cells have never been shown to have any clinical benefit in patients with heart disease.","author":{"name":"MedPage Today","url":"http:\/\/www.medpagetoday.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/262\/normal\/Screen_Shot_2016-02-09_at_10.51.03.png?1455015082"}}],"twitter":[{"url":"http:\/\/twitter.com\/Capricor_News\/statuses\/755514555686490113","license":"gnip","citation_ids":[4687474],"posted_on":"2016-07-19T21:28:01+00:00","author":{"name":"Capricor Therapeutic","url":"http:\/\/capricor.com","image":"https:\/\/pbs.twimg.com\/profile_images\/491689017075720192\/Ua6MdTiF_normal.jpeg","description":"(Nasdaq:CAPR), a biotechnology company focused on the discovery, development & commercialization of first-in-class therapeutics for the treatment of diseases.","id_on_source":"Capricor_News","tweeter_id":"2670600336","geo":{"lt":34.05223,"ln":-118.24368,"country":"US"},"followers":1907},"tweet_id":"755514555686490113"},{"url":"http:\/\/twitter.com\/TrialsLoop\/statuses\/756980703833620480","license":"gnip","citation_ids":[4687474],"posted_on":"2016-07-23T22:33:58+00:00","author":{"name":"TrialsLoop","url":"http:\/\/www.trialsloop.com","image":"https:\/\/pbs.twimg.com\/profile_images\/822376116765634560\/vun4G6zD_normal.jpg","description":"#mClinical cloud based platform for #patientengagement, retention, and post-market observation in #clinicaltrials. #digitalhealth #wearabletech  #mClinical","id_on_source":"TrialsLoop","tweeter_id":"741459029604474880","geo":{"lt":32.71533,"ln":-117.15726,"country":"US"},"followers":275},"tweet_id":"756980703833620480"},{"url":"http:\/\/twitter.com\/StemCellMarket\/statuses\/759793886004908032","license":"gnip","citation_ids":[4687474],"posted_on":"2016-07-31T16:52:33+00:00","author":{"name":"BioInformant","url":"http:\/\/www.bioinformant.com","image":"https:\/\/pbs.twimg.com\/profile_images\/631935077631442948\/pmuWfApm_normal.jpg","description":"As the 1ST and ONLY market research firm to specialize in the #stemcell industry, BioInformant has been cited by WSJ, Xconomy, and Vogue. [Cade Hildreth, CEO]","id_on_source":"StemCellMarket","tweeter_id":"2612311915","geo":{"lt":38.91706,"ln":-77.00025,"country":"US"},"followers":20286},"tweet_id":"759793886004908032"},{"url":"http:\/\/twitter.com\/drjosorio\/statuses\/759803566433247233","license":"gnip","rt":["StemCellMarket"],"citation_ids":[4687474],"posted_on":"2016-07-31T17:31:01+00:00","author":{"name":"Joel I. Osorio, MD","url":"http:\/\/www.regenerage.clinic","image":"https:\/\/pbs.twimg.com\/profile_images\/719152549056491520\/9lRnMSJB_normal.jpg","description":"VP Clinical Development at #Bioquark,Inc.@RegenerAgeMD @ReAnima_Neuro #Fellow on #Regenerative #StemCell #Medicine and #Biotech Board #Certified by the #A4M","id_on_source":"drjosorio","tweeter_id":"187417393","geo":{"lt":19.42847,"ln":-99.12766,"country":"MX"},"followers":1594},"tweet_id":"759803566433247233"}],"facebook":[{"title":"Timeline Photos","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1821158941447138&id=1516139925282376","license":"public","citation_ids":[4687474],"posted_on":"2016-07-19T21:24:18+00:00","summary":"The ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) trial is a Phase I\/II #clinicaltrial evaluating the safety and efficacy of lead therapeutic candidate, CAP-1002 \u2013 Capricor\u2019s allogeneic, off-the-shelf, cardiosphere-derived cell p","author":{"name":"Capricor Therapeutics, Inc.","url":"https:\/\/www.facebook.com\/1516139925282376","facebook_wall_name":"Capricor Therapeutics, Inc.","image":"https:\/\/graph.facebook.com\/1516139925282376\/picture","id_on_source":"1516139925282376"}}]}}